Fulgent Announces 2026 Revenue Guidance and Advances AI Diagnostic Integration
Fulgent (FLGT) has provided full-year 2026 revenue guidance of $330 million to $340 million following its third-quarter earnings report. The company reported a strong cash position of $652.4 million, bolstered by a federal tax refund, which provides significant financial flexibility as laboratory collections continue to recover from previous billing software transition delays. Key operational highlights include the rapid scaling of Fulgent's diagnostic AI platform, which saw a 23% sequential increase in slide image analysis volume with a technical failure rate of only 0.01%. Additionally, the company is advancing its oncology pipeline, specifically moving its nanoencapsulated therapy candidate FID-007 closer to Phase 3 clinical trials following discussions with the FDA.
Coverage
- Fulgent Announces 2026 Revenue Guidance and Advances AI Diagnostic Integration
- Trifast signals revised H2 guidance as it targets double-digit EBIT margins over the medium term
- Inhabit Announces AI Advancements and Product Integrations at OPTECH 2026
- TKO Raises 2026 Revenue Guidance and Accelerates Share Buybacks
- Five9 Announces Acquisition of Level AI and Raises 2026 AI Revenue Guidance
- SenesTech outlines plan to add at least one more salesperson by year-end as Q3 revenue reaches $1.1M
- Five9 Reports Q3 Revenue Beat and Outlines AI Growth Strategy via Level AI Acquisition